

BIOCON GROUP

FINANCIALS

Q4 FY 2006 vs Q4 FY 2005

FY 2006 vs FY 2005

FACT SHEET

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT
(Rs. crores)

Particulars	Q4 FY 2006	Q4 FY 2005	Variance Q4 FY 06 vs Q4 FY 05	Full Year ended March 31, 2006	Full Year ended March 31, 2005	Variance FY 06 vs FY 05
<u>INCOME</u>						
Sales-Biopharmaceuticals	157	132	20%	603	557	8%
Sales- Enzymes	25	24	2%	85	90	-5%
Contract research	32	19	70%	100	66	52%
Total Sales	214	175	23%	788	713	11%
Other income	1	3		5	15	
Total Income / Revenues	215	178	20%	793	728	9%
<u>EXPENDITURE</u>						
Material & Power Costs	122	100	22%	434	383	13%
Staff costs	15	13	16%	62	57	9%
Other expenses	17	12	37%	63	49	31%
Manufacturing, staff & other exps	154	125	23%	559	489	14%
PBDIT /EBIDTA	61	53	15%	234	239	-2%
Interest and finance charges	1	-		2	2	
PBDT	60	53	13%	232	237	-2%
Depreciation	8	7		29	22	
PBT	52	46	13%	203	215	-6%
Taxes	5	4		31	18	
PROFIT FOR THE PERIOD	47	42	12%	172	197	-12%
Add/(less): Minority interest	1	-		2	1	
PAT	48	42	13%	174	198	-12%
EPS on issued capital (Rs)	4.8	4.2	13%	17.4	19.8	-12%

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		
Particulars	As at 31-Mar-06	As at 31-Mar-05
<u>SOURCES OF FUNDS</u>		
Share Capital	50	50
Reserves & Surplus	838	691
Total Shareholder's Funds	888	741
Minority interest	3	1
Deferred Tax Liability	30	23
Secured Loans	68	49
Unsecured Loans	37	27
Total Loan Funds	105	76
Total	1,026	841
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	827	578
Investments	100	235
Inventories	110	74
Sundry debtors	224	183
Cash and bank balances	2	3
Loans and advances	24	17
Total Current Assets, Loans & Advances	360	277
Less: Current liabilities and provisions	261	249
Net Current assets	99	28
Total	1,026	841

BIOCON LIMITED (CONSOLIDATED)		
STATEMENT OF CASH FLOWS		<i>(Rs. crores)</i>
Particulars	Full Year ended Mar 31, 2006	Full Year ended March 31, 2005
<u>I. Cash Flow from Operating Activities</u>		
Net profit before tax	203	215
Less/Add: non-cash items/ items required separately		
Depreciation	30	22
Others	(2)	(10)
Changes in working capital and other provisions	(137)	(43)
Cash generated from operations	94	184
Tax paid (net of refunds)	(23)	(12)
Net Cash provided by operating activities	71	172
<u>II. Cash Flow from Investing Activities</u>		
Fixed Assets	- 229	(285)
Change in minority Interest	4	(1)
Interest / dividend received	5	13
Investments	142	(213)
Net cash used for investing activities	(79)	(485)
<u>III. Cash Flows from Financing Activities</u>		
Borrowings and other financing activities	5	(2)
Net Cash provided/(used) for financing activities	5	(2)
<u>IV. Net Change in Cash and Cash Equivalents (I+II+III)</u>		
	(3)	(315)
<u>V. Cash & Cash Eq. at the beginning of the year</u>	3	318
<u>VI CASH AND CASH EQUIVALENTS OF THE ESOP TRUST ACQUIRED DURING THE YEAR</u>	2	0
<u>VII. Cash and Cash Eq. at the end of the year (IV+V+VI)</u>	2	3